4.6 Article

Identification of a Peptide Inhibitor of the RPM-1.FSN-1 Ubiquitin Ligase Complex

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 289, Issue 50, Pages 34654-34666

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M114.614065

Keywords

axon; Caenorhabditis elegans (C; elegans); Cell Signaling; Neurodegeneration; Ubiquitin Ligase; F-box; FSN-1; Neuronal Development

Funding

  1. National Institutes of Health [R01 NS072129]
  2. National Science Foundation [IOS-1121095]

Ask authors/readers for more resources

Background: How RPM-1 interacts with FSN-1 remains unknown. Results: Structure-function and transgenic analysis define the biochemical relationship between RPM-1 and FSN-1. Conclusion: RPM-1 uses a conserved mechanism to bind FSN-1 that is independent of RPM-1 ubiquitin ligase activity. Significance: Our biochemical and genetic analysis has led to identification of RIP, an in vivo inhibitor of the RPM-1FSN-1 ubiquitin ligase complex. The Pam/Highwire/RPM-1 (PHR) proteins include: Caenorhabditis elegans RPM-1 (Regulator of Presynaptic Morphology 1), Drosophila Highwire, and murine Phr1. These important regulators of neuronal development function in synapse formation, axon guidance, and axon termination. In mature neurons the PHR proteins also regulate axon degeneration and regeneration. PHR proteins function, in part, through an ubiquitin ligase complex that includes the F-box protein FSN-1 in C. elegans and Fbxo45 in mammals. At present, the structure-function relationships that govern formation of this complex are poorly understood. We cloned 9 individual domains that compose the entire RPM-1 protein sequence and found a single domain centrally located in RPM-1 that is sufficient for binding to FSN-1. Deletion analysis further refined FSN-1 binding to a conserved 97-amino acid region of RPM-1. Mutagenesis identified several conserved motifs and individual amino acids that mediate this interaction. Transgenic overexpression of this recombinant peptide, which we refer to as the RPM-1FSN-1 complex inhibitory peptide (RIP), yields similar phenotypes and enhancer effects to loss of function in fsn-1. Defects caused by transgenic RIP were suppressed by loss of function in the dlk-1 MAP3K and were alleviated by point mutations that reduce binding to FSN-1. These findings suggest that RIP specifically inhibits the interaction between RPM-1 and FSN-1 in vivo, thereby blocking formation of a functional ubiquitin ligase complex. Our results are consistent with the FSN-1 binding domain of RPM-1 recruiting FSN-1 and a target protein, such as DLK-1, whereas the RING-H2 domain of RPM-1 ubiquitinates the target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available